Originally reported by hastingstribune. Read more
Archive summary Clinical & research
Azurity Pharmaceuticals Announces the Availability of ARYNTATM (lisdexamfetamine dimesylate) ...
Woburn, MA, April 06, 2026 (GLOBE NEWSWIRE) -- Azurity Pharmaceuticals, Inc. announced that ARYNTATM (lisdexamfetamine dimesylate) Oral Solution is now available in the United States for treating ADHD in adults and pediatric patients 6 years and older. Arynta, a ready-to-use...
Newsletter
The weekly digest
Weekly digest of US behavioral health policy and regulation, source-linked and practitioner-edited. Free; unsubscribe in one click.